Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFFINITY: Phase 2 Basket Study of Atrasentan in Proteinuric Glomerular Diseases
2020-004176-18Phase 2Active
- Sponsor
- Chinook Therapeutics
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atrasentan in glomerulopathy and IgA nephropathy (IgAN), sponsored by Chinook Therapeutics. Primary endpoint: Change in proteinuria/albuminuria. Started Feb 2021; status: active.
02
Drugs
atrasentan
03
Conditions
glomerulopathyIgA nephropathy (IgAN)
Beyond the preview
Go deeper on 2020-004176-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004176-18.